Impavido FDA Approval History
Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.
Development Timeline for Impavido
|Mar 19, 2014||FDA Approves Impavido to Treat Tropical Disease Leishmaniasis|
|Nov 13, 2013||Paladin Announces Extension of the Impavido PDUFA Date by Three Months|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.